Philogen S.p.a.
Clinical trials sponsored by Philogen S.p.a., explained in plain language.
-
Injected drug cocktail takes aim at tough skin cancer
Disease control Not yet recruitingThis study tests three different injected drugs (L19IL2, L19TNF, or a mix of both) for people with advanced basal cell skin cancer who cannot or choose not to have surgery or radiation. About 180 participants will receive weekly injections for four weeks and be followed for up to…
Phase: PHASE2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new combination of two drugs (L19IL2 and ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 …
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New shot therapy targets hard-to-treat skin cancer in phase 2 trial
Disease control Not yet recruitingThis study tests a new treatment for people with advanced skin cancer (squamous cell carcinoma) that has stopped responding to or cannot tolerate standard immunotherapy. The treatment is a combination of two drugs (L19IL2 and L19TNF) injected directly into the tumors once a week …
Phase: PHASE2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New shot combo targets tough skin cancers when other treatments fail
Disease control Not yet recruitingThis study tests a new drug combination (L19IL2 and L19TNF) injected directly into skin tumors for people with advanced basal cell carcinoma that has worsened or cannot be treated with standard therapies. About 92 participants will receive weekly injections for up to two 4-week c…
Phase: PHASE2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated May 06, 2026 16:15 UTC